Neoadjuvant therapy before radical prostatectomy: where have we been? Where are we going? (Q36701418)

15 August 2017

1 reference

title

Neoadjuvant therapy before radical prostatectomy: where have we been? Where are we going? (English)

1 reference

15 August 2017

John Pendleton

1

1 reference

15 August 2017

Louis L Pisters

2

1 reference

15 August 2017

Kogenta Nakamura

3

1 reference

15 August 2017

Satoshi Anai

4

1 reference

15 August 2017

Charles J Rosser

5

1 reference

15 August 2017

publication date

1 January 2007

1 reference

15 August 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Urologic Oncology

1 reference

15 August 2017

volume

25

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

11-18

1 reference

Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the Canadian experience

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Role of neoadjuvant treatment in clinically confined prostate cancer. Takeda NHT Italian Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

National practice patterns and time trends in androgen ablation for localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Neoadjuvant hormonal therapy: the Canadian experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Tr

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Preoperative endocrine therapy for clinical stage A2, B, and C prostate cancer: an interim report on short-term effects. Prostate Cancer Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Effects of 3 Months' Neoadjuvant Hormonal Treatment with a GnRH Analogue (Triptorelin) prior to Radical Retropubic Prostatectomy on Prostate-Specific Antigen and Tumour Volume in Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

A multicentre trial of combined neoadjuvant androgen blockade with Zoladex and flutamide prior to radical prostatectomy in prostate cancer. The European Study Group on Neoadjuvant Treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Nondetected tumor (pT0) after prolonged, neoadjuvant treatment of localized prostatic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Prognosis of stage pT0 after prolonged neoadjuvant endocrine therapy of prostate cancer: a matched-pair analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Complete response following preoperative chemotherapy for resectable non-small cell lung cancer: accuracy of clinical assessment using the French trial database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Single-agent chemotherapy with docetaxel significantly reduces PSA levels in patients with high-grade localized prostate cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2006.03.005

10.1016/J.UROLONC.2006.03.005

7 January 2021

Identifiers

DOI

1 reference

15 August 2017

1 reference